BMY•benzinga•
Reported Earlier, 2seventy bio Agrees To Be Acquired By Bristol Myers Squibb For $5.00 Per Share In 88% Premium Transaction Valued At $286M
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 11, 2025 by benzinga